CytoPatch – the “hands-free” manual patch platform
Gigohm seals without enhancers
Data quality of manual path clamp
Can be a collection solution for analytical support
The platform chosen by the FDA
The Cytopatch is a robotic AI patch clamp platform designed to mimic a manual patch rig. This platform offers cell capture and sealing with quartz glass electrodes, seal resistances of 2 G? or greater without the need for seal enhancers, recordings at physiologic temperatures, and perfusion of the well for multiple concentration exposures. Because of its high data quality, flexibility, and throughput, the CytoPatch is an excellent choice for any lab wanting the performance of a manual patch clamp rig but with a much-enhanced throughput.
The base CytoPatch unit sells for $175,000, and CytoBioScience also sells microchips, buffers, solutions, cells, and specific types of shipping containers to researchers on a recurring basis, Garvin says. CytoBioscience, which changed its name last year, was founded in Germany and moved to San Antonio in 2015. Regulatory filings show CytoBioScience had raised about $15.8 million as of August 2016.
Routine applications include: recording ion currents in expression systems and recording ion currents and action potentials in iPS-CM or native adult cardiac myocytes. Because of its unique perfusion system, data can be obtained from difficult to record currents such as ligand activated currents and currents which desensitize rapidly.
The Cytopatch is the choice for anyone who wants the power of a manual patch clamp setup with the throughput of an automated platform at a competitive price.
They just did a $1.5 million non-dilutive offering so they're flush with cash now. ($1.53 million equity round of funding)
From the 8K - "Each of these revenue-generating segments; instruments, consumables and contract research, is a leader in its technology and in its capacity. Having undergone years of testing, starting, restarting, and honing its development into the cutting edge it is today, the Company is experiencing accelerating revenue growth and is well-positioned to reach its potential."
Also: "The market is experiencing strong growth, driven by both regulation and rising demand for outsourced safety pharmacological work.
The company is engaged with both private and public partners globally, including the FDA."